Home
About
Overview
Sharing Data
ORCID
Help
History (17)
Neoplasms, Basal Cell
Phase II study of Cediranib (AZD 2171), an inhibitor of the vascular endothelial growth factor receptor, for second-line therapy of small cell lung cancer (National Cancer Institute #7097).
Fetal thermal effects of diagnostic ultrasound.
Imaging wisely: patient safety in CT.
Perspectives on Drug Development in Multiple Myeloma-Looking Forward to 2025.
See All 17 Pages
Find People
Find Everything
Login
to edit your profile (add a photo, awards, links to other websites, etc.)
Edit My Profile
My Person List (
0
)
Return to Top
Perspectives on Drug Development in Multiple Myeloma-Looking Forward to 2025.
Perspectives on Drug Development in Multiple Myeloma-Looking Forward to 2025. Clin Cancer Res. 2022 01 01; 28(1):23-26.
View in:
PubMed
subject areas
Humans
Multiple Myeloma
Mutation
Precision Medicine
authors with profiles
Andrzej Jakubowiak